隐球菌性脑膜炎试验中分级复合终点的DOOR与Win Ratio评价
该研究在隐球菌性脑膜炎临床试验中评估分级复合终点的可行性。德尔菲调查34名应答者多数将死亡与严重不良事件列为首要优先。对三项随机临床试验的再分析显示,单剂量脂质体两性霉素B的BDP为55%(95%CI 51%-59%)、win ratio为1.23(95%CI 1.03-1.46);口服两性霉素B与舍曲林辅助治疗未显示统计学显著差异。
要点
- 分级复合终点在隐球菌性脑膜炎试验中可行,可提升临床相关性
- DOOR提供绝对排名,win ratio提供相对疗效估计,二者互补
- 在关注安全性与耐受性的非劣效设计中尤有价值
核心结论
- 分级复合终点在隐球菌性脑膜炎临床试验中可行,可增强临床相关性,尤其适用于安全性与耐受性重要的非劣效设计。
- DOOR与win ratio两种统计方法提供互补视角:DOOR给出绝对排名,win ratio提供更易解释的相对疗效估计。
研究设计与样本
- 对三项隐球菌性脑膜炎随机临床试验进行再分析,采用win ratio与DOOR分析分级复合终点。
- 通过德尔菲调查确定复合终点构建的优先顺序,共收到34名应答者。
主要发现
- AMBITION-cm试验中单剂量脂质体两性霉素B的BDP为55%(95%CI 51%-59%),win ratio为1.23(95%CI 1.03-1.46),显示优于标准治疗。
关键数值与推荐
- 德尔菲调查多数应答者将死亡与严重不良事件列为复合终点的优先项目。
- DOOR提供绝对排名,win ratio提供相对治疗效应估计,两者互补。
临床怎么用
- 在隐球菌性脑膜炎试验设计中可考虑采用分级复合终点以纳入安全性与耐受性等患者关切的结局。
- 解读结果时可结合BDP的绝对排名与win ratio的相对效应,尤其关注非劣效设计中的安全性差异。
局限性
- 本研究为对三项既有随机临床试验的再分析,非前瞻性验证。
- 德尔菲调查应答者为34人,样本有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Traditional antifungal trials have relied on all-cause mortality as the primary endpoint, which may overlook important treatment-related outcomes such as adverse events or tolerability. METHODS: We evaluated the use of hierarchical composite endpoints to capture clinically meaningful treatment differences in cryptococcal meningitis trials. A Delphi survey determined priorities in constructing the composite endpoint. We analyzed three randomized clinical trials on cryptococcal meningitis with win ratio and the Desirability of Outcome Ranking (DOOR). We estimated the Better DOOR Probability (BDP), which is the probability that a participant assigned to the study treatment would have a more desirable outcome. RESULTS: The Delphi survey received 34 respondents and most of them prioritized mortality and serious adverse events. In the AMBITION-cm trial, single-dose liposomal amphotericin B yielded a BDP of 55% (95% CI, 51%-59%) and win ratio of 1.23 (95% CI, 1.03-1.46), indicating superiority over standard-of-care therapy. In ENACT phase II trial, oral amphotericin B was associated with BDP of 52% (95% CI, 42%-63%) and win ratio of 1.14 (95% CI, .68-1.91), showing no statistically significant difference. The ASTRO-CM trial testing adjunctive sertraline showed no overall benefit with sertraline using either BDP (46%; 95% CI, 41%-52%) or win ratio 0.87 (95% CI, .70-1.08). CONCLUSIONS: Hierarchical composite endpoints were feasible to implement in cryptococcal meningitis clinical trials and can enhance clinical relevance, especially in noninferiority designs where safety and tolerability matter. The two statistical approaches provided complementary perspectives-DOOR offering absolute ranks and win ratio providing a more interpretable relative treatment effect estimate.
引用
- Dai B, Engen N, Skipper CP, et al. Evaluating Desirability of Outcome Ranking (DOOR) and Win Ratio for Hierarchical Composite Endpoints in Cryptococcal Meningitis Trials. Clin Infect Dis. 2026. PMID: 41495969. doi:10.1093/cid/ciaf719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。